Bioventus Inc Total Assets
Bioventus Inc total assets. Based on the latest financial reports, Bioventus Inc (BVS) holds total assets worth $673.35 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see BVS market cap for the company's overall valuation and market capitalisation.
Total Assets of Bioventus Inc (2014–2025)
Total assets of Bioventus Inc from 2014 to 2025. This chart illustrates how Bioventus Inc's total assets have evolved over time, based on quarterly financial data. See BVS share price today for real-time trading data and today's change.
Bioventus Inc - Asset Composition Analysis
Bioventus Inc Total Assets Breakdown (December 2025)
Bioventus Inc total assets breakdown as of December 2025. Bioventus Inc's total assets of $673.35 Million consist of 39.9% current assets and 60.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.5% |
| Accounts Receivable | $128.30 Million | 18.8% |
| Inventory | $82.24 Million | 12.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $368.42 Million | 53.9% |
| Goodwill | $7.46 Million | 1.1% |
Asset Composition Trend (2014–2025)
This chart illustrates how Bioventus Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Bioventus Inc to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bioventus Inc's current assets represent 39.9% of total assets in 2025, an increase from 22.1% in 2014.
- Cash Position: Cash and equivalents constituted 7.5% of total assets in 2025, up from 3.7% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 54.0% of total assets, a decrease from 74.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 53.9% of total assets.
Bioventus Inc Competitors by Total Assets
Key competitors of Bioventus Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
BMC Medical Co. Ltd. A
SHE:301367
|
China | CN¥3.59 Billion |
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $96.98 Million |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
|
Sequana Medical NV
BR:SEQUA
|
Belgium | €14.57 Million |
|
Hironic Co. Ltd
KQ:149980
|
Korea | ₩80.01 Billion |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩131.65 Billion |
Bioventus Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.69 | 1.48 | 1.53 |
| Quick Ratio | 1.17 | 0.96 | 1.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $105.08 Million | $89.52 Million | $85.37 Million |
Bioventus Inc - Advanced Valuation Insights
This section examines the relationship between Bioventus Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.91 |
| Latest Market Cap to Assets Ratio | 1.09 |
| Asset Growth Rate (YoY) | -6.1% |
| Total Assets | $683.56 Million |
| Market Capitalization | $747.60 Million USD |
Valuation Analysis
Above Book Valuation: The market values Bioventus Inc's assets above their book value (1.09x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Bioventus Inc's assets decreased by 6.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Bioventus Inc (2014–2025)
The table below shows the annual total assets of Bioventus Inc from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $683.56 Million | -6.10% |
| 2024-12-31 | $727.96 Million | -10.23% |
| 2023-12-31 | $810.91 Million | -40.92% |
| 2022-12-31 | $1.37 Billion | +11.97% |
| 2021-12-31 | $1.23 Billion | +147.92% |
| 2020-12-31 | $494.47 Million | +4.67% |
| 2019-12-31 | $472.41 Million | +6.70% |
| 2018-12-31 | $442.72 Million | -9.16% |
| 2015-12-31 | $487.35 Million | +13.23% |
| 2014-12-31 | $430.42 Million | -- |
About Bioventus Inc
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis… Read more